Using a modified Delphi process and a structured evidence-grading framework, experts reviewed data on: - COVID-19 and influenza vaccine efficacy - Adverse events related to CSIs - Effects of CSIs on the hypothalamicpituitary axis - Incidence of COVID-19 and influenza in patients receiving CSIs - Appropriate intervals between CSIs and vaccination Key Recommendations: For non-urgent indications, offer CSIs at least 1 week before or after COVID-19 or influenza vaccination
It's been studied for its potential to promote wound healing, tissue repair, and other health benefits, particularly in the context of injuries and inflammation
Standard BPC-157 dosing Typical dose: 250-500 mcg subcutaneously 1-2 times daily [24]
Joint pain patients typically feel the anti-inflammatory effect at 2 to 3 weeks, with structural support benefits accumulating at 4 to 6 weeks
5 It has a longer half-life which means that the body produces growth hormones after injection
No evidence of significant endocrine disruption, hepatic, or cardiovascular adverse effects has been observed in available data when used within researched dose ranges
